Yahoo Finance • 3 days ago
We recently published a list of 15 Stocks with Buy Ratings that Hedge Funds Love. In this article, we are going to take a look at where Natera, Inc. (NASDAQ:NTRA) stands against other stocks with buy ratings that hedge funds love. The U.S... Full story
Yahoo Finance • 4 days ago
Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund firm, Duquesne Capital Management, for 30 years, posting eye-popping average annual returns of 30%. While Druckenmill... Full story
Yahoo Finance • 24 days ago
1 Mid-Cap Stock to Own for Decades and 2 to Brush Off Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of... Full story
Yahoo Finance • 2 months ago
Insights from the Fourth Quarter 2024 13F Filing Stanley Druckenmiller (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2024, providing insights into his investment moves during this period. Stanley Druckenm... Full story
Yahoo Finance • 7 months ago
Shows nearly 10x advantage in overall survival at 36 months based on ctDNA status and affirms Signatera’s ability to predict chemotherapy benefit Shows a 50% reduction in risk of death for Signatera-positive patients when treated with ACT... Full story
Yahoo Finance • 7 months ago
With the latest round of 13F filings released over the past month, investors and market watchers alike are interested in seeing where the major hedge fund managers are finding value opportunities. Background Managers with more than $100... Full story
Yahoo Finance • 7 months ago
We recently compiled a list of the Morgan Stanley's Highest Conviction Stocks: Top 20 Stocks To Buy.In this article, we are going to take a look at where Natera, Inc. (NASDAQ:NTRA) stands against Morgan Stanley's other high conviction stoc... Full story
Yahoo Finance • 8 months ago
AUSTIN, Texas, August 06, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference... Full story
Yahoo Finance • 11 months ago
In this article, we will take a detailed look at the 10 Cathie Wood Stocks Insiders are Selling. For a quick overview of such stocks, read our article5 Cathie Wood Stocks Insiders are Selling. There was a time Cathie Wood talked about her... Full story
Yahoo Finance • last year
SEC and Chief Legal Officer Daniel Rabinowitz has sold 2,160 shares of Natera Inc (NASDAQ:NTRA) on March 5, 2024, according to a recent SEC filing. The transaction was reported in a Form 4 document filed with the SEC, which can be accessed... Full story
Yahoo Finance • last year
Herm Rosenman, a director at Natera Inc (NASDAQ:NTRA), sold 93,901 shares of the company on February 16, 2024, according to a recent SEC Filing. Natera Inc is a diagnostics company specializing in the field of genetic testing. The company'... Full story
Yahoo Finance • last year
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics company, grappling with a substantial $1.... Full story
Yahoo Finance • last year
Study shows ctDNA positivity is the most prognostic factor, demonstrating the potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer AUSTIN, Texas, February 05, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: N... Full story
Yahoo Finance • last year
AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows ctDNA status in patients with gastric and gas... Full story
Yahoo Finance • last year
2023 revenues are expected to be approximately $20 million above top end of guidance AUSTIN, Texas, January 09, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced prelimin... Full story
Yahoo Finance • last year
In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story
Yahoo Finance • last year
Pan-cancer study showed MTM/mL dynamics were more predictive of therapy response than mVAF dynamics, with an observed hazard ratio nearly 2x higher AUSTIN, Texas, December 21, 2023--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global l... Full story
Yahoo Finance • last year
In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there's one t... Full story
Yahoo Finance • last year
In a recent transaction on November 20, 2023, Steven Chapman, the CEO and President of Natera Inc, sold 2,566 shares of the company. This move has caught the attention of investors and analysts, as insider transactions can often provide va... Full story
Yahoo Finance • last year
Natera, Inc. (NASDAQ:NTRA) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you for standing by and welcome to the Natera Inc. Q3 Earnings Conference Call. All lines have been placed on mute to prevent any background nois... Full story